Oncternal therapeutics, inc. (GTXI)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash and cash equivalents

16,019

20,051

23,096

28,516

21,012

20,645

23,089

16,511

14,958

15,816

53,431

5,156

7,771

8,910

8,238

9,572

12,063

14,056

11,797

14,323

14,163

17,880

9,627

11,178

22,432

14,529

19,283

28,252

36,136

48,044

38,731

47,319

55,909

63,745

73,296

82,421

58,181

Short-term Investments

-

-

-

-

175

-

-

-

-

28,083

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Short-term investments

-

-

-

-

-

-

14,984

29,205

17,186

-

200

6,200

8,740

12,959

5,200

10,200

12,200

15,200

22,663

25,111

30,437

31,415

1,915

6,080

5,345

200

1,675

3,390

6,085

8,045

8,555

8,610

8,045

10,695

9,715

8,535

450

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,152

908

925

981

830

904

683

FARESTON sale proceeds receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21,671

-

-

-

-

-

-

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

105

146

161

150

143

171

Prepaid and other assets

545

736

959

1,355

1,347

565

2,071

1,864

2,067

2,178

2,049

2,130

2,240

2,429

2,096

2,064

2,295

2,633

2,458

1,856

743

856

919

1,194

1,278

442

830

1,002

1,375

726

1,233

1,223

1,498

1,266

1,351

1,077

875

Total current assets

16,564

20,787

24,055

29,871

22,534

21,210

40,144

47,580

34,211

46,077

55,680

13,486

18,751

24,298

15,534

21,836

26,558

31,889

36,918

41,290

45,343

50,151

12,461

18,452

29,055

15,171

21,788

32,644

43,596

56,815

71,342

58,165

66,523

76,848

85,342

93,080

60,360

Right-of-use asset

154

190

226

265

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

1,047

767

768

767

-

752

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment, net

-

-

-

-

12

-

28

35

43

51

57

65

73

81

89

11

12

5

8

12

16

29

42

58

86

112

217

285

389

507

640

779

890

1,096

1,302

1,526

2,040

Intangible assets, net

-

-

-

-

90

-

97

101

105

108

112

116

119

123

126

130

134

137

-

-

-

-

-

-

-

-

-

-

-

-

186

201

198

-

264

221

1,850

Intangible and other assets, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

852

558

423

471

513

625

652

322

487

562

713

452

-

-

-

712

-

-

-

Total assets

17,765

21,744

25,049

30,903

22,636

21,962

40,269

47,716

34,359

46,236

55,849

13,667

18,943

24,502

15,749

21,977

26,704

32,031

37,778

41,860

45,782

50,651

13,016

19,135

29,793

15,605

22,492

33,491

44,698

57,774

72,168

59,145

67,611

78,656

86,908

94,827

64,250

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

1,376

871

1,231

2,765

609

3,440

3,121

1,473

1,739

2,604

2,451

603

514

1,220

1,223

1,387

903

382

184

797

438

512

179

992

619

808

1,253

1,796

1,100

1,707

1,214

1,462

937

1,219

829

1,139

848

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27,349

30,078

70,798

27,782

30,430

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

-

-

-

-

1,210

-

6,184

6,404

7,871

5,371

6,828

4,582

4,243

3,391

2,141

2,143

2,116

2,441

3,204

1,573

1,647

1,850

2,139

2,711

3,894

3,759

3,912

6,503

7,049

7,788

-

-

-

4,614

-

-

-

Accrued liabilities

2,778

2,731

2,435

2,550

-

891

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,263

5,732

4,671

-

4,367

3,765

3,112

Deferred grant revenue

3,062

3,640

3,008

2,387

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current portion of lease liability

101

99

96

139

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue - current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,345

Total current liabilities

7,317

7,341

6,770

7,841

1,819

4,331

9,305

7,877

9,610

7,975

9,279

5,185

4,757

4,611

3,364

3,530

3,019

30,172

33,466

73,168

29,867

32,792

2,318

3,703

4,513

4,567

5,165

8,299

8,149

9,495

11,477

7,194

5,608

5,833

5,196

4,904

5,305

Preferred stock warrant liability

-

-

1,300

1,300

-

674

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability

53

91

129

126

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, less current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

6,721

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

30

82

147

195

354

389

436

488

578

786

262

235

949

240

217

497

Commitments and contingencies (Notes 3)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Convertible preferred stock, $0.0001 par value; authorized shares - none and 130,100 at December 31, 2019 and 2018, respectively; issued and outstanding – none and 8,148 at December 31, 2019 and 2018, respectively; liquidation preference of none and $48,954 at December 31, 2019 and 2018, respectively

-

-

-

-

-

46,588

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stockholders’ equity:
Common stock, $0.001 par value; authorized shares – 60,000 at March 31, 2020 and December 31, 2019; issued and outstanding shares – 15,392 and 15,387 at March 31, 2020 and December 31, 2019, respectively

15

15

15

15

24

5

24

24

23

22

22

16

16

16

142

142

142

14

140

140

140

140

76

76

75

63

63

63

63

63

63

63

63

63

63

63

52

Additional paid-in capital

80,690

79,869

79,551

79,445

-

1,748

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

-

-

-

-

626,650

-

625,580

625,024

599,920

599,876

598,908

552,322

551,621

551,073

536,577

535,725

534,911

515,319

514,413

513,659

512,910

512,460

490,766

490,500

489,357

465,981

464,445

463,326

461,829

460,887

460,073

459,261

458,959

457,985

456,901

455,791

404,555

Accumulated deficit

-70,310

-65,572

-61,416

-56,524

-605,857

-31,384

-594,640

-585,209

-575,194

-561,637

-552,360

-543,856

-537,451

-531,198

-524,334

-517,420

-511,368

-513,474

-510,241

-545,107

-497,155

-494,771

-480,226

-475,291

-464,347

-455,360

-447,570

-438,633

-425,831

-413,249

-400,231

-407,635

-397,254

-386,174

-375,492

-366,148

-352,880

Total stockholders’ equity

10,395

14,312

18,150

22,936

20,817

-29,631

30,964

39,839

24,749

38,261

46,570

8,482

14,186

19,891

12,385

18,447

23,685

1,859

4,312

-31,308

15,895

17,829

10,616

15,285

25,085

10,684

16,938

24,756

36,061

47,701

59,905

51,689

61,768

71,874

81,472

89,706

51,727

Total liabilities and stockholders’ equity

17,765

21,744

25,049

30,903

22,636

21,962

40,269

47,716

34,359

46,236

55,849

13,667

18,943

24,502

15,749

21,977

26,704

32,031

37,778

41,860

45,782

50,651

13,016

19,135

29,793

15,605

22,492

33,491

44,698

57,774

72,168

59,145

67,611

78,656

86,908

94,827

64,250